Biocryst Pharmaceuticals (BCRX) Common Equity (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Common Equity of -$553.8 million for Q1 2026, down 364.82% on a QoQ basis from -$119.2 million in Q4 2025, and down 22.55% year-over-year from -$715.1 million in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Common Equity (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at -$553.8 million for Q1 2026.
- Quarterly Common Equity fell 22.55% year-over-year to -$553.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$553.8 million (down 22.55% YoY) and the FY2025 annual result came in at -$119.2 million, up 74.96% from the prior year.
- Common Equity was -$553.8 million for Q1 2026 at Biocryst Pharmaceuticals, down from -$119.2 million in the prior quarter.
- Across five years, Common Equity topped out at -$119.2 million in Q4 2025 and bottomed at -$553.8 million in Q1 2026.
- A 5-year average of -$372.3 million and a median of -$411.0 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 175.36% — and 2025, when it surged 74.96%.
- Biocryst Pharmaceuticals' Common Equity stood at -$294.6 million in 2022, then sank by 54.63% to -$455.5 million in 2023, then fell by 4.48% to -$475.9 million in 2024, then jumped by 74.96% to -$119.2 million in 2025, then sank by 364.82% to -$553.8 million in 2026.
- Business Quant data shows BCRX's Common Equity at -$553.8 million in Q1 2026, -$119.2 million in Q4 2025, and -$387.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -553.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -553.84 Mn |
| Dec 31, 2025 | -119.15 Mn |
| Sep 30, 2025 | -387.89 Mn |
| Jun 30, 2025 | -421.59 Mn |
| Mar 31, 2025 | -451.93 Mn |
| Dec 31, 2024 | -475.93 Mn |
| Sep 30, 2024 | -468.56 Mn |
| Jun 30, 2024 | -475.61 Mn |
| Mar 31, 2024 | -476.17 Mn |
| Dec 31, 2023 | -455.53 Mn |
| Sep 30, 2023 | -410.99 Mn |
| Jun 30, 2023 | -388.71 Mn |
| Mar 31, 2023 | -328.29 Mn |
| Dec 31, 2022 | -294.60 Mn |
| Sep 30, 2022 | -242.66 Mn |
| Jun 30, 2022 | -213.23 Mn |
| Mar 31, 2022 | -164.22 Mn |
| Dec 31, 2021 | -106.99 Mn |
| Sep 30, 2021 | -147.04 Mn |
| Jun 30, 2021 | -106.08 Mn |